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Tuberculosis is the major cause of morbidity and mortality in HIV-
infected patients in sub-Saharan Africa. HIV infection is often first 
diagnosed following a diagnosis of tuberculosis, with many patients 
needing antiretroviral therapy (ART). Starting ART in HIV-infected 
patients with tuberculosis (TB) may be associated with complications, 
including side-effects from co-administration of multiple drugs with 
many overlapping toxicities, reductions in concentrations of certain 
antiretroviral drugs following the induction of metabolising enzymes 
and drug transporters by rifampicin, and paradoxical deterioration 
due to the immune reconstitution inflammatory syndrome (IRIS). 
Furthermore, the high pill burden of co-treatment could reduce 
adherence, resulting in poor treatment outcomes for both diseases. 
These potential harms must be weighed against the high mortality 
rates in patients with HIV-associated tuberculosis who do not receive 
ART, especially those with low CD4 counts. The optimal time to 
initiate ART in patients with tuberculosis is an important research 
question, and randomised controlled trials are addressing this issue. 
Interim results of the South African Starting Antiretroviral 
Therapy at Three Points in Tuberculosis Therapy (SAPIT) study have 
been published in the New England Journal of Medicine.1 The SAPIT 
investigators are the first group to publish controlled data on when to 
initiate ART in patients with TB. Patients with sputum smear-positive 
pulmonary TB and CD4 counts below 500 cells/µl were randomised 
to start ART in one of three phases of TB treatment: within 4 weeks 
of starting TB therapy; within 4 weeks after the completion of the 
intensive phase of TB therapy (2 or 3 months of 4 or 5 anti-TB drugs 
for patients with new or retreatment TB, respectively); or within 
4 weeks after the completion of TB treatment (6 or 8 months for 
patients with new or retreatment TB, respectively). Recruitment 
into the latter group (the sequential arm) was stopped prematurely 
by the Data Safety Monitoring Board (DSMB) when it was found 
that mortality was significantly higher in this group compared with 
the groups that started ART during TB therapy. Mortality largely 
occurred in patients with CD4 counts below 200 cells/µl. The groups 
starting ART during and after the intensive phase of TB treatment 
completed enrolment, and results are still pending. 
When the SAPIT study was done we believe that their trial design 
was appropriate to investigate the optimal treatment strategy for the 
sub-set of patients with CD4 cell counts in the range 200 - 500 cells/µl. 
In contrast, however, we believe that it was predictable that patients 
with advanced disease (CD4 counts <200 cells/µl) would experience 
higher mortality if ART was deferred for a long period and that these 
patients should not have been enrolled. These views were expressed 
in a letter and a short commentary, and on blogs by bioethicists 
and clinicians.2-5 The SAPIT investigators and several international 
researchers have defended the study design.3-7 However, none of these 
forums allowed for a thorough exploration of the ethical issues and 
the evidence related to outcomes in patients with HIV-associated TB 
that was available when the SAPIT study was conducted.
We explore in greater detail the key ethical issues raised by the 
SAPIT study and the relevant clinical evidence available to the 
researchers at the time the study started. The latter point is important, 
as people who have defended the SAPIT study have accused critics of 
employing current evidence rather than evidence that was available 
when the study commenced in mid-2005.6,7 We do not question 
the integrity of the researchers who conducted the study, several of 
whom are highly respected for their considerable contributions to 
HIV research in Africa. Responsibility for ethical study design and 
protection of patients participating in research is shared between 
investigators, ethics committees, regulatory bodies, and data and 
safety monitoring boards. We believe that people involved in research 
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involving human subjects at all these levels can learn important 
lessons from the issues raised by the SAPIT study.
Clinical evidence
African studies, including three from South Africa, have reported 
mortality rates of patients with HIV-associated TB not on ART 
stratified by the degree of immune suppression.8-12 We extracted data 
on mortality at 6 months from these studies, as this is the duration of 
TB therapy for patients with first episodes of TB (Table I). All studies 
show dramatic increases in mortality as CD4 declines, with 6-month 
mortality rates of 17% to 51% in patients with CD4 counts of 200 
cells/µl and below. Three studies showed that mortality in patients 
with CD4 counts below 200 cells/µl was similar in patients with and 
without TB.8,10,11 Patients in the SAPIT study were all sputum smear 
positive and received prophylactic co-trimoxazole, both of which 
are associated with lower mortality.13,14 Nevertheless it is clear that 
mortality is high during the course of TB therapy in patients with 
advanced HIV disease without ART.
The most important potential cause of harm resulting from starting 
ART with TB therapy is the development of IRIS, which occurs more 
commonly with earlier initiation of ART. At the time the SAPIT study 
started a systematic review of IRIS related to mycobacterial infections 
was published – the authors described life-threatening IRIS reactions 
in patients with TB, but failed to find a single fatal case reported in 
the literature.15 A more recent meta-analysis estimated the incidence 
of paradoxical TB IRIS to be 15%, with mortality among these of 
3%.16 Extrapolating from these data, an estimated 0.45% of patients 
with HIV-associated TB starting ART die as a result of paradoxical 
TB IRIS. 
Apart from IRIS, the complications of co-treatment with ART 
and TB drugs have not been associated with increased mortality. 
Rifampicin, a key component of TB therapy, induces many drug-
metabolising enzymes and drug transporters, which can lead to 
reductions in concentrations of the non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), used in first-line ART regimens, 
and may impair responses to ART. At the time of the SAPIT study it 
was recognised that efavirenz was the preferred NNRTI to be used 
with rifampicin-based TB therapy, with limited but good outcome 
data, and this was recommended in both the national and World 
Health Organization (WHO) guidelines implemented at the time.17,18 
Efavirenz was used in the SAPIT study. Data on overlapping drug 
toxicities of ART and TB drugs were limited at the time of the SAPIT 
study, but we found no evidence to suggest that these were associated 
with an increased risk of mortality. 
Two retrospective studies, published before the SAPIT study 
started, showed reductions in mortality and new opportunistic 
diseases in patients starting ART during TB therapy compared with 
those who deferred ART.19,20 Another study found that outcomes were 
similar for patients without TB starting ART and for those starting 
ART during TB treatment.21 
In summary, the evidence available to the SAPIT investigators 
when the study started showed that HIV-infected patients with CD4 
counts below 200 cells/µl have high mortality during TB treatment, 
that TB IRIS is associated with a low risk of mortality (with none 
reported when the SAPIT study started), that effective ART regimens 
were available that could be taken with TB treatment, and that ART 
reduced mortality when commenced during TB treatment. 
The cited studies to obtain this evidence are observational. 
Randomised controlled trials provide a better level of evidence 
than observational studies, as the randomisation process should 
ensure that groups are well matched – this is the main rationale for 
the SAPIT study. However, numerous randomised controlled trials 
have been done on ART regimens over the past two decades. The 
monotherapy antiretroviral era was the last time that no therapy 
or placebo was used for patients with advanced HIV disease. 
Once reductions in mortality had been shown with monotherapy, 
subsequent trials compared monotherapy with dual therapy, and 
then dual therapy with triple therapy, which resulted in dramatic 
reductions in mortality and is the current standard of ART care.22 
The key point is that ART is directed at suppressing HIV 
replication, resulting in gradual recovery of the immune system. The 
benefit of ART in reducing the frequency of opportunistic diseases 
and mortality follows from this immune recovery. ART has no direct 
effect on any opportunistic diseases such as TB. Any study of the 
timing of initiation of ART for HIV-associated complications must be 
mindful of the extensive evidence base that exists for ART. 
Ethical issues
Equipoise
For randomisation to occur, published data should show conflicting 
or ambiguous results resulting in substantial clinical uncertainty, so 
that at the time of randomisation there is an equal (balanced) risk 
of individual patients experiencing either harm or benefit in any of 
the study arms.23 This situation is called equipoise. The investigators 
of the SAPIT study have claimed that there was equipoise, with the 
principal investigator stating ‘When you put them on ARVs, they 
died. When you didn’t, they died. We were at sea.’3 As discussed, 
we found evidence that ART significantly reduced mortality in 
patients with HIV-associated TB and could not find fatal cases of TB 
IRIS reported in the literature before the SAPIT study started. The 
other complications of TB/HIV co-treatment are unlikely to cause 
significant increases in mortality. In our view, none of the concerns 
about TB/HIV co-treatment overrules the high risk of untreated HIV 
infection in patients with advanced disease.
The SAPIT investigators also argued7 that the 2003 WHO ART 
guidelines18 support their view that there was equipoise, citing the 
Table I. Six-month mortality of patients with HIV-associated 
TB by CD4 stratum in studies of African patients without 
access to ART published before 2005
Mortality by CD4 stratum
Country Type of TB
CD4 count         Mortality 
(µl)                     (%)
Uganda8* Sputum smear 
positive 
>200                      1
≤200                     17
South Africa9 Sputum culture 
positive 
>28%†                     0
14 - 28%†               8
<14%†                   22
Gambia10* Pulmonary and 
extrapulmonary
>500                        0
200 - 500              15
<200                     51
South Africa11* Pulmonary and 
extrapulmonary
>400                      8
200 - 400              20
<200                    32
South Africa12 Sputum culture 
positive
>500                      8
200 - 499              10
<200                    38
*These studies reported mortality over time as a continuous function, so 6-month mortal-
ity was obtained from Kaplan-Meier survival graphs using digitising software (Enguage 
digitiser version 4.1).
†CD4 of <14% is regarded as equivalent to CD4 count of <200 cells/µl.
570 September 2010, Vol. 100, No. 9  SAMJ
FORUM
following text: ‘The optimal time to initiate ART in patients with TB 
is not known.’ 
The WHO guidelines go on to state (italics our emphasis): 
‘Case-fatality rates in many patients with TB during the first 2 
months of TB treatment are high, particularly when they present 
with advanced HIV disease, and ART in this setting might be life-
saving. On the other hand, pill burden, drug-to-drug interaction, 
potential toxicity and immune reconstitution syndrome should be 
kept in mind when deciding on the best time to begin treatment … 
Pending current studies, WHO recommends that ART in patients 
with CD4 cell counts below 200/mm3 be started between two weeks 
and two months after the start of TB therapy, when the patient has 
stabilized on this therapy. This provisional recommendation is meant 
to encourage rapid initiation of therapy in patients among whom there 
may be a high mortality rate. However, deferring the start of ART 
may be reasonable in a variety of clinical scenarios. For example, in 
patients with higher CD4 cell counts the commencement of ART may 
be delayed until after the induction phase of TB therapy is completed 
in order to simplify the management of treatment.’ 
We agree with these views in the 2003 WHO ART guidelines. For 
patients with CD4 counts below 200 cells/µl there was equipoise for 
comparing different time-points for starting ART during the intensive 
phase of TB treatment (or possibly shortly after the intensive phase, 
as with one group in the SAPIT trial). For patients with CD4 counts 
above 200 cells/µl there may have been equipoise for starting ART 
shortly after TB treatment. 
Standard of care
Ethical principles for medical research involving human subjects in 
the World Medical Association’s Declaration of Helsinki24 recommend 
that ‘the best current’ intervention should be provided as the standard 
of care to patients in studies, including those in the control group, 
except when there is no intervention (which is not the case for 
HIV infection) or ‘where for compelling and scientifically sound 
methodological reasons the use of placebo is necessary to determine 
the efficacy or safety of an intervention and the patients who receive 
placebo or no treatment will not be subject to any risk of serious 
or irreversible harm’. The latter point is intended primarily for 
conditions with minor morbidity, and they go on to state: ‘Extreme 
care must be taken to avoid abuse of this option.’ The Declaration of 
Helsinki is internationally recommended for medical research and all 
research projects in South Africa should abide by its principles.
Insisting on the ‘best current’ standard of care has been criticised, 
as standards of care may differ in high- and low-income countries, 
and important research could be stifled in developing countries.25 The 
WHO 2003 ART guidelines18 differed substantially from guidelines 
for high-income countries at the time (e.g. standardised regimens, 
lower CD4 threshold for starting ART), but set the standard of care 
for resource-limited settings and allowed for rapid scale-up of ART 
globally. 
The 2004 South African ART guidelines,17 largely based on the 
WHO guidelines, recommended the following for starting ART 
in patients with TB: ‘If the patient has a history of WHO stage IV 
illness, and/or a CD4 count of less than 200 cells/mm3, complete 2 
months of TB therapy before commencing ART. If the patient has a 
CD4 count of less than 50 cells/mm3, or other serious HIV-related 
illnesses, make sure that the patient is tolerating TB treatment before 
initiating ART.’ 
Consequently, care for patients in the group who delayed ART until 
after TB treatment in the SAPIT study with CD4 counts below 200 
cells/µl was below the standard of care. On ethical considerations of 
the standard of care, Lie et al. state: ‘Participants should not be denied 
any treatments with significant benefits that they would ordinarily 
receive. In this sense, research participants should be no worse off 
than they would be if they did not participate in the trial.’25 Patients 
in Durban with HIV-associated TB and CD4 counts below 200 cells/
µl would have been better off had they been given the prescribed 
standard of care in the South African health system at the time rather 
than enrolled into the sequential arm of the SAPIT study.
The SAPIT investigators argue that patient safety in the deferred 
ART group was ensured by the protocol allowing clinicians to start 
ART at any point if the patients deteriorated.7 We do not accept 
that this ensures patient safety, as patients with low CD4 counts 
may appear relatively well one day and then deteriorate rapidly 
with life-threatening conditions such as bacterial infections or 
pneumocystis pneumonia. It may be too late at this point to intervene 
with ART, which works by suppressing viral replication, resulting 
in improvement of CD4 count and function. This takes months to 
achieve in most patients. 
Suggestions for a way forward
The issues we have raised have implications for the future conduct 
of clinical trials and patient safety in South Africa. Research ethics 
committees face a daunting task, with the explosion of medical 
knowledge making it difficult for them to find appropriate independent 
reviewers for research protocols from their own institutions. One 
option would be the development of a South African registry of 
reviewers, which would need to respect the intellectual property of the 
research protocols. Investigators should provide detailed information 
on the current standard of care, and any study offering less than 
this standard should undergo wide consultation before the study 
is passed. Research ethics committees should consider requesting 
reviews from other institutions, locally and internationally, more 
frequently than at present, especially with interventional studies. 
It is not mandatory for studies to be passed by research ethics 
committees/institutional review boards of the institutions of all 
investigators, except under certain circumstances (e.g. if the funding 
comes from a foreign institution and the research is conducted in 
South Africa, then the foreign investigator institutions should also 
review the study). However, it is desirable that studies be reviewed 
by all these institutions, as this increases the chances that problems 
can be identified. Finally, the ethical training of investigators and the 
capacity of ethics committees in South Africa should be improved.
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